 Jeffrey Bennett
Concepts (494)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 75 | 2023 | 114 | 15.680 |
Why?
| | Aquaporin 4 | 52 | 2023 | 86 | 7.380 |
Why?
| | Multiple Sclerosis | 32 | 2023 | 380 | 6.360 |
Why?
| | Immunoglobulin G | 50 | 2023 | 781 | 4.680 |
Why?
| | Autoantibodies | 46 | 2024 | 1360 | 4.550 |
Why?
| | Optic Neuritis | 15 | 2023 | 37 | 4.450 |
Why?
| | B-Lymphocytes | 15 | 2023 | 773 | 1.860 |
Why?
| | Optic Nerve | 12 | 2023 | 65 | 1.760 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 31 | 1.670 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 15 | 2024 | 43 | 1.610 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 25 | 1.480 |
Why?
| | Astrocytes | 13 | 2022 | 163 | 1.360 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 128 | 1.150 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1265 | 1.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 15 | 2023 | 667 | 1.130 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 75 | 1.080 |
Why?
| | Neuroglia | 4 | 2018 | 150 | 1.070 |
Why?
| | Retinal Degeneration | 2 | 2023 | 30 | 0.920 |
Why?
| | Complement System Proteins | 7 | 2019 | 288 | 0.900 |
Why?
| | Epitopes | 7 | 2023 | 438 | 0.900 |
Why?
| | Humans | 130 | 2024 | 115741 | 0.890 |
Why?
| | Natalizumab | 4 | 2020 | 46 | 0.880 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 666 | 0.860 |
Why?
| | Methylprednisolone | 1 | 2023 | 83 | 0.850 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 30 | 0.830 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 106 | 0.810 |
Why?
| | Autoimmunity | 4 | 2017 | 822 | 0.790 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 72 | 0.780 |
Why?
| | Immunotherapy | 4 | 2020 | 479 | 0.760 |
Why?
| | Animals | 54 | 2023 | 32104 | 0.750 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 30 | 0.730 |
Why?
| | Brain | 8 | 2019 | 2373 | 0.730 |
Why?
| | Cerebellum | 3 | 2018 | 200 | 0.710 |
Why?
| | Disease Models, Animal | 14 | 2022 | 3580 | 0.690 |
Why?
| | Complement Activation | 4 | 2022 | 343 | 0.670 |
Why?
| | Inflammation | 11 | 2023 | 2500 | 0.670 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 3 | 2023 | 50 | 0.670 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 18 | 0.660 |
Why?
| | Plasma Cells | 7 | 2017 | 57 | 0.660 |
Why?
| | Complement C1q | 1 | 2019 | 38 | 0.650 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 22 | 0.650 |
Why?
| | Remyelination | 1 | 2018 | 8 | 0.640 |
Why?
| | Aminopyridines | 1 | 2019 | 81 | 0.630 |
Why?
| | Cell Membrane | 3 | 2017 | 683 | 0.630 |
Why?
| | Central Nervous System | 5 | 2023 | 239 | 0.630 |
Why?
| | Papilledema | 4 | 2023 | 38 | 0.630 |
Why?
| | Magnetic Resonance Imaging | 11 | 2023 | 3122 | 0.620 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 69 | 0.610 |
Why?
| | Microglia | 2 | 2019 | 203 | 0.610 |
Why?
| | Pyrroles | 1 | 2019 | 185 | 0.600 |
Why?
| | Organic Chemicals | 1 | 2019 | 116 | 0.600 |
Why?
| | Immunologic Factors | 4 | 2022 | 220 | 0.600 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 381 | 0.590 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 54 | 0.580 |
Why?
| | Glucocorticoids | 2 | 2019 | 552 | 0.580 |
Why?
| | Disease Management | 2 | 2018 | 563 | 0.580 |
Why?
| | CHO Cells | 8 | 2019 | 140 | 0.570 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.560 |
Why?
| | Antigens, CD19 | 5 | 2022 | 97 | 0.560 |
Why?
| | Mice | 29 | 2023 | 15052 | 0.560 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 113 | 0.560 |
Why?
| | Retina | 5 | 2023 | 266 | 0.550 |
Why?
| | Myelin Sheath | 6 | 2023 | 145 | 0.550 |
Why?
| | Cricetulus | 7 | 2019 | 99 | 0.550 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 36 | 0.540 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1243 | 0.540 |
Why?
| | Mutagenesis | 2 | 2019 | 170 | 0.510 |
Why?
| | Stents | 2 | 2016 | 477 | 0.500 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 123 | 0.480 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 85 | 0.480 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 48 | 0.470 |
Why?
| | Optic Atrophy | 2 | 2011 | 10 | 0.460 |
Why?
| | Temporal Arteries | 4 | 2015 | 47 | 0.450 |
Why?
| | Adult | 34 | 2023 | 30789 | 0.440 |
Why?
| | Visual Acuity | 6 | 2021 | 273 | 0.430 |
Why?
| | Flow Cytometry | 9 | 2023 | 1083 | 0.420 |
Why?
| | Antigens, Viral | 3 | 2015 | 177 | 0.420 |
Why?
| | Glial Fibrillary Acidic Protein | 4 | 2023 | 79 | 0.420 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 92 | 0.410 |
Why?
| | Axons | 2 | 2022 | 179 | 0.410 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 45 | 0.400 |
Why?
| | Recurrence | 7 | 2023 | 953 | 0.400 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 4 | 0.400 |
Why?
| | Hemodynamics | 1 | 2016 | 1024 | 0.390 |
Why?
| | Biomarkers | 8 | 2023 | 3471 | 0.390 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 71 | 0.380 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 36 | 0.380 |
Why?
| | Cricetinae | 6 | 2019 | 260 | 0.380 |
Why?
| | Peptide Fragments | 3 | 2017 | 675 | 0.380 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 143 | 0.380 |
Why?
| | Gene Targeting | 1 | 2011 | 75 | 0.380 |
Why?
| | Spinal Cord | 7 | 2016 | 351 | 0.370 |
Why?
| | Nerve Degeneration | 1 | 2010 | 40 | 0.370 |
Why?
| | Middle Aged | 31 | 2023 | 27069 | 0.370 |
Why?
| | Eye Diseases | 2 | 2020 | 76 | 0.370 |
Why?
| | Stilbenes | 1 | 2010 | 36 | 0.370 |
Why?
| | Mice, Inbred C57BL | 10 | 2023 | 4773 | 0.360 |
Why?
| | Nerve Regeneration | 1 | 2010 | 53 | 0.360 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 535 | 0.350 |
Why?
| | Female | 47 | 2023 | 60018 | 0.350 |
Why?
| | Double-Blind Method | 7 | 2023 | 1660 | 0.350 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 38 | 0.350 |
Why?
| | Rats | 12 | 2021 | 5033 | 0.340 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 19 | 0.340 |
Why?
| | Meningioma | 2 | 2023 | 78 | 0.340 |
Why?
| | Immune System Phenomena | 1 | 2009 | 2 | 0.340 |
Why?
| | Virus Diseases | 1 | 2011 | 200 | 0.330 |
Why?
| | Cell Survival | 2 | 2019 | 1024 | 0.330 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2000 | 0.320 |
Why?
| | Nervous System Diseases | 2 | 2020 | 253 | 0.320 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 93 | 0.310 |
Why?
| | Neurology | 2 | 2007 | 85 | 0.310 |
Why?
| | Ophthalmology | 2 | 2007 | 77 | 0.300 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 123 | 0.300 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 92 | 0.300 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1756 | 0.290 |
Why?
| | Antibodies | 3 | 2017 | 374 | 0.290 |
Why?
| | Mutation | 6 | 2019 | 3364 | 0.290 |
Why?
| | Proteomics | 2 | 2012 | 859 | 0.280 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 21 | 0.280 |
Why?
| | Immunization, Passive | 3 | 2020 | 80 | 0.280 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 41 | 0.280 |
Why?
| | Adolescent | 16 | 2023 | 17922 | 0.270 |
Why?
| | Corpus Callosum | 1 | 2006 | 57 | 0.270 |
Why?
| | Protein Binding | 6 | 2019 | 1917 | 0.270 |
Why?
| | Antibody Formation | 1 | 2007 | 273 | 0.270 |
Why?
| | Atrophy | 2 | 2023 | 152 | 0.260 |
Why?
| | Young Adult | 13 | 2023 | 10518 | 0.260 |
Why?
| | Herpes Zoster | 3 | 2015 | 333 | 0.260 |
Why?
| | Male | 33 | 2022 | 56050 | 0.250 |
Why?
| | Syndecan-1 | 4 | 2011 | 28 | 0.250 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 26 | 0.250 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 168 | 0.250 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 18 | 0.250 |
Why?
| | Acute Disease | 3 | 2018 | 914 | 0.240 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 37 | 0.240 |
Why?
| | Risk Assessment | 4 | 2021 | 2990 | 0.230 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1357 | 0.230 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 27 | 0.230 |
Why?
| | Blindness, Cortical | 1 | 2003 | 5 | 0.230 |
Why?
| | Peptide Library | 4 | 2011 | 81 | 0.230 |
Why?
| | Prospective Studies | 8 | 2023 | 6276 | 0.230 |
Why?
| | Proteolipids | 1 | 2023 | 28 | 0.230 |
Why?
| | Proteoglycans | 1 | 2004 | 107 | 0.230 |
Why?
| | Oligodendroglia | 2 | 2017 | 149 | 0.220 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 170 | 0.220 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 757 | 0.220 |
Why?
| | Epitope Mapping | 4 | 2017 | 51 | 0.220 |
Why?
| | Neuroprotection | 1 | 2023 | 30 | 0.220 |
Why?
| | Seroconversion | 1 | 2023 | 46 | 0.220 |
Why?
| | Immune System | 1 | 2004 | 173 | 0.210 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 221 | 0.210 |
Why?
| | Vision Disorders | 2 | 2021 | 130 | 0.210 |
Why?
| | Cells, Cultured | 7 | 2016 | 3914 | 0.210 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 148 | 0.210 |
Why?
| | Mice, Transgenic | 5 | 2018 | 1970 | 0.200 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2790 | 0.200 |
Why?
| | Aged | 16 | 2021 | 19294 | 0.200 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 431 | 0.200 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 501 | 0.200 |
Why?
| | Protein Isoforms | 4 | 2017 | 339 | 0.200 |
Why?
| | Autoantigens | 4 | 2020 | 398 | 0.190 |
Why?
| | Antibody Affinity | 2 | 2019 | 52 | 0.190 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 165 | 0.190 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 21 | 0.190 |
Why?
| | Internationality | 2 | 2019 | 145 | 0.190 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 25 | 0.190 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1057 | 0.180 |
Why?
| | Cell Proliferation | 3 | 2020 | 2194 | 0.180 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 34 | 0.180 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 34 | 0.180 |
Why?
| | Azathioprine | 1 | 2020 | 50 | 0.180 |
Why?
| | Interferon-gamma | 1 | 2023 | 726 | 0.170 |
Why?
| | Viral Vaccines | 1 | 2020 | 90 | 0.170 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 32 | 0.170 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.170 |
Why?
| | Cell Separation | 2 | 2015 | 293 | 0.170 |
Why?
| | Steroids | 1 | 2020 | 147 | 0.170 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 279 | 0.170 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 12 | 0.170 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 383 | 0.160 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 56 | 0.160 |
Why?
| | Communicable Diseases | 1 | 2020 | 130 | 0.160 |
Why?
| | Cell Lineage | 1 | 2020 | 310 | 0.160 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 8 | 0.160 |
Why?
| | Oxidoreductases | 1 | 2019 | 92 | 0.160 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 8 | 0.160 |
Why?
| | Peptides | 2 | 2019 | 864 | 0.160 |
Why?
| | Retrospective Studies | 9 | 2023 | 12633 | 0.160 |
Why?
| | Animals, Newborn | 2 | 2018 | 780 | 0.160 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.150 |
Why?
| | Treatment Outcome | 10 | 2021 | 9162 | 0.150 |
Why?
| | Point Mutation | 1 | 2019 | 217 | 0.150 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 60 | 0.150 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 72 | 0.150 |
Why?
| | Mice, Knockout | 9 | 2017 | 2604 | 0.150 |
Why?
| | Cohort Studies | 5 | 2022 | 4949 | 0.150 |
Why?
| | Antibodies, Viral | 4 | 2023 | 527 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 693 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 443 | 0.150 |
Why?
| | Child | 11 | 2023 | 18503 | 0.150 |
Why?
| | Spatial Analysis | 1 | 2017 | 20 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.140 |
Why?
| | Skull Neoplasms | 1 | 2017 | 21 | 0.140 |
Why?
| | Sphenoid Bone | 1 | 2017 | 15 | 0.140 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 73 | 0.140 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 40 | 0.140 |
Why?
| | Orbital Diseases | 1 | 2017 | 25 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4442 | 0.140 |
Why?
| | Albumins | 1 | 2017 | 91 | 0.140 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 90 | 0.140 |
Why?
| | Microvessels | 1 | 2017 | 68 | 0.140 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 327 | 0.140 |
Why?
| | Interleukin-6 | 1 | 2020 | 677 | 0.140 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6423 | 0.140 |
Why?
| | Fibrinogen | 1 | 2017 | 160 | 0.140 |
Why?
| | HEK293 Cells | 4 | 2022 | 602 | 0.140 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 299 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 509 | 0.130 |
Why?
| | Ethics, Research | 1 | 2015 | 34 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3256 | 0.130 |
Why?
| | Treatment Failure | 1 | 2016 | 332 | 0.130 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 5 | 0.130 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 7 | 0.130 |
Why?
| | Models, Molecular | 2 | 2017 | 1390 | 0.130 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 402 | 0.130 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 209 | 0.130 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 344 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.120 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 66 | 0.120 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 1 | 0.120 |
Why?
| | Visual Pathways | 2 | 2007 | 44 | 0.120 |
Why?
| | Plasma Exchange | 1 | 2014 | 12 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2019 | 594 | 0.120 |
Why?
| | Alanine | 1 | 2015 | 103 | 0.120 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 804 | 0.120 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 81 | 0.120 |
Why?
| | Nerve Fibers | 1 | 2015 | 87 | 0.120 |
Why?
| | Glycine | 1 | 2015 | 156 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1870 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 930 | 0.120 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1537 | 0.120 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 245 | 0.120 |
Why?
| | Erythropoietin | 1 | 2014 | 72 | 0.120 |
Why?
| | Transcriptome | 2 | 2020 | 736 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2262 | 0.110 |
Why?
| | Placenta Diseases | 1 | 2013 | 13 | 0.110 |
Why?
| | Proteome | 2 | 2015 | 345 | 0.110 |
Why?
| | Fetal Death | 1 | 2013 | 49 | 0.110 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.110 |
Why?
| | Biomedical Research | 1 | 2019 | 589 | 0.110 |
Why?
| | Antibody Specificity | 2 | 2011 | 176 | 0.110 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 9 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 1893 | 0.110 |
Why?
| | Phenotype | 3 | 2020 | 2839 | 0.110 |
Why?
| | Computer Simulation | 1 | 2017 | 884 | 0.110 |
Why?
| | Syndrome | 2 | 2019 | 339 | 0.100 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 22 | 0.100 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 83 | 0.100 |
Why?
| | Quality of Life | 1 | 2023 | 2388 | 0.100 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 145 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1335 | 0.100 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 98 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 616 | 0.100 |
Why?
| | Antigens, CD20 | 2 | 2023 | 28 | 0.100 |
Why?
| | Exanthema | 1 | 2013 | 77 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2017 | 696 | 0.100 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.100 |
Why?
| | Area Postrema | 1 | 2011 | 1 | 0.100 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 5 | 0.100 |
Why?
| | Cranial Sinuses | 1 | 2011 | 12 | 0.100 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 13 | 0.100 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 29 | 0.100 |
Why?
| | Fundus Oculi | 1 | 2011 | 40 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2015 | 645 | 0.100 |
Why?
| | Cerebral Angiography | 2 | 2011 | 111 | 0.100 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 102 | 0.100 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 67 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3343 | 0.090 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 6 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 157 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2013 | 230 | 0.090 |
Why?
| | Databases, Factual | 1 | 2015 | 1139 | 0.090 |
Why?
| | Cell Line | 3 | 2011 | 2651 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1500 | 0.090 |
Why?
| | Spinal Puncture | 1 | 2009 | 19 | 0.090 |
Why?
| | Research Design | 1 | 2015 | 946 | 0.090 |
Why?
| | Time Factors | 4 | 2015 | 6171 | 0.080 |
Why?
| | Brain Injuries | 1 | 2014 | 451 | 0.080 |
Why?
| | Genes | 1 | 2009 | 224 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 2013 | 431 | 0.080 |
Why?
| | Risk Factors | 3 | 2015 | 8702 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2011 | 449 | 0.080 |
Why?
| | Blindness | 1 | 2008 | 37 | 0.080 |
Why?
| | Optic Disk | 1 | 2008 | 36 | 0.080 |
Why?
| | Clone Cells | 3 | 2017 | 248 | 0.080 |
Why?
| | Transfection | 3 | 2018 | 866 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 621 | 0.080 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 29 | 0.080 |
Why?
| | Age of Onset | 2 | 2020 | 450 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 15 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 14 | 0.070 |
Why?
| | Interferon-beta | 1 | 2008 | 79 | 0.070 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 250 | 0.070 |
Why?
| | Molecular Biology | 2 | 2009 | 56 | 0.070 |
Why?
| | Visual Fields | 1 | 2007 | 77 | 0.070 |
Why?
| | Health | 1 | 2007 | 74 | 0.070 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 6 | 0.070 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.070 |
Why?
| | Measles virus | 1 | 2006 | 11 | 0.070 |
Why?
| | Bevacizumab | 1 | 2007 | 118 | 0.070 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 24 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 84 | 0.070 |
Why?
| | Vitreous Body | 1 | 2007 | 102 | 0.070 |
Why?
| | Puerperal Disorders | 1 | 2007 | 31 | 0.070 |
Why?
| | Binding, Competitive | 2 | 2019 | 200 | 0.070 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 47 | 0.070 |
Why?
| | Models, Immunological | 1 | 2006 | 92 | 0.070 |
Why?
| | Child, Preschool | 4 | 2021 | 9138 | 0.060 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 2751 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 216 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1024 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 102 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 314 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 702 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1356 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 503 | 0.060 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.060 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 243 | 0.060 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 43 | 0.060 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 16 | 0.060 |
Why?
| | Risk | 1 | 2007 | 819 | 0.060 |
Why?
| | Patient Selection | 1 | 2008 | 654 | 0.060 |
Why?
| | Granzymes | 1 | 2024 | 40 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 42 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2129 | 0.060 |
Why?
| | Feasibility Studies | 1 | 2006 | 748 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 198 | 0.060 |
Why?
| | Neurons | 3 | 2017 | 1298 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2023 | 67 | 0.060 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 12 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 10 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 18 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2423 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 92 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1056 | 0.050 |
Why?
| | Complement Inactivating Agents | 1 | 2023 | 41 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 164 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 57 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 127 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 41 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 88 | 0.050 |
Why?
| | Antigens, Surface | 1 | 2022 | 151 | 0.050 |
Why?
| | Eye | 1 | 2002 | 101 | 0.050 |
Why?
| | Binding Sites | 2 | 2017 | 1177 | 0.050 |
Why?
| | Glycoproteins | 1 | 2023 | 309 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 398 | 0.050 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 31 | 0.050 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 7 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 537 | 0.050 |
Why?
| | Base Sequence | 1 | 2004 | 2114 | 0.040 |
Why?
| | Pregnancy | 3 | 2013 | 5553 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 175 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 337 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2020 | 3037 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 112 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 85 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1646 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 701 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 149 | 0.040 |
Why?
| | Serum | 1 | 2019 | 57 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2021 | 271 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 162 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 816 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 49 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1219 | 0.040 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 255 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2009 | 327 | 0.040 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 14 | 0.040 |
Why?
| | Recovery of Function | 1 | 2021 | 577 | 0.040 |
Why?
| | Clonal Deletion | 1 | 2017 | 18 | 0.040 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 15 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.040 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 145 | 0.040 |
Why?
| | Craniotomy | 1 | 2017 | 67 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 198 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1230 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 59 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 134 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 135 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1598 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 101 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 160 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 3 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 498 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 445 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 795 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 326 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 281 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 325 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 353 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 492 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 42 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 388 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 39 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 332 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 211 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 21 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2911 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2393 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 35 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 18 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 62 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 183 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 395 | 0.030 |
Why?
| | Narcolepsy | 1 | 2013 | 19 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 630 | 0.030 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 19 | 0.030 |
Why?
| | Pyrans | 1 | 2012 | 3 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2420 | 0.030 |
Why?
| | Vaccination | 1 | 2020 | 1210 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 166 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2015 | 386 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 102 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 82 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 36 | 0.030 |
Why?
| | Phlebography | 1 | 2011 | 40 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 225 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 8 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2586 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 204 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 511 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 193 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1384 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 271 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 124 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 60 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 569 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 324 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 126 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 941 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 214 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 123 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 1765 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 203 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1473 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 114 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 37 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 35 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 649 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 8 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 362 | 0.020 |
Why?
| | Water | 1 | 2012 | 412 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1642 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 147 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 138 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2269 | 0.020 |
Why?
| | B-Lymphocyte Subsets | 1 | 2009 | 68 | 0.020 |
Why?
| | Virion | 1 | 2009 | 74 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 325 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 208 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 274 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 438 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 793 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 401 | 0.020 |
Why?
| | Glioma | 1 | 2010 | 296 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 351 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2335 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 965 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1168 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1853 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 724 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4448 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1147 | 0.020 |
Why?
| | Infant | 1 | 2017 | 7979 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 6 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 9 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 10 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1103 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 732 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 684 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 537 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1218 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2353 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1405 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 4541 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 4669 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|